Brands
MG Motor teams up with para-athlete & Arjuna awardee Deepa Malik
MUMBAI: MG Motor India has announced Paralympic athlete and Khel Ratna Awardee Deepa Malik to be the voice of the personal AI assistant in its upcoming SUV – MG Astor to deliver a unique voice experience to its consumers as it looks to disrupt the Indian automotive industry.
Called ‘The Woman on Wheels’, Deepa Malik has enlisted herself in the record books for several driving feats across deserts & mountains. The woman extraordinaire will humanise the voice of the personal AI assistant in the soon-to-be launched SUV MG Astor, it said in a media statement.
Talking about the partnership, MG Motor India president & managing director, Rajeev Chaba, said, “At MG, we strive to consistently create exciting and meaningful experiences for our customers. In another first, we are introducing a personal AI assistant in MG Astor. Having Deepa Malik, a woman of many firsts, as a voice for Astor, is in line with our commitment to both community and diversity. Deepa is the epitome of women empowerment and her voice in Astor is a message for everyone to be unstoppable.”
Deepa Malik, the first Indian woman Paralympic medalist, said, “I am delighted to be the voice of the next MG SUV. I have closely followed MG’s journey in India, and I applaud their vision. MG has not only led the disruption in the automotive industry, but it has contributed to the empowerment of different sections of society. It is commendable that MG’s one-third of the active workforce is women. I am confident that MG will emerge as a champion with the industry-leading features of Astor.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
